Drug, across the briefings

Sunitinib across 14 cancers

Sunitinib appears in 14 of the briefings; its FDA label names 3 of those diseases.

Disease	FDA label	Open Targets stage, on which gene	Trials	Active
Gastrointestinal stromal tumour	label names disease	phase 4 on KIT, PDGFRA	126	28
Kidney cancer	label names disease	phase 4 on KDR	267	20
Small intestine cancer	label names disease	phase 4 on KIT, PDGFRA	2	0
Acute myeloid leukemia		phase 4 on FLT3, KIT	14	0
Gastric cancer		phase 4 on KDR	24	2
Glioblastoma		phase 4 on PDGFRA	24	0
Hepatocellular carcinoma		phase 4 on KDR	26	4
Lower-grade glioma		phase 4 on PDGFRA	—	—
Lung cancer		phase 4 on RET	58	4
Melanoma		phase 4 on KIT	26	4
Osteosarcoma		phase 4 on KDR	8	4
Soft tissue sarcoma		phase 4 on PDGFRA, PDGFRB	18	0
Testicular cancer		phase 4 on KIT	2	0
Thyroid cancer		phase 4 on RET	12	0

The label column is the briefing's openFDA stage: a label whose Indications and Usage names the disease. The Open Targets column is the furthest clinical stage recorded for the drug against any gene on that briefing's target list, in any indication. Trials are ClinicalTrials.gov interventional studies naming the drug and the disease, from the briefing's trials stage; a dash means the briefing did not search this drug in that disease (it searches the drugs Open Targets lists against its own genes), which is not the same as none. Salt forms, biosimilar suffixes and formulation words are merged by the same rule the briefings use.